Breast Cancer Trial, Recruiting NCT05831878 Sponsor: RenJi Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05831878
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are female and aged 18 or older
  • People whose doctors expect them to live for at least 12 weeks
  • People who are fully active or have only minor restrictions in physical activity (this is measured using a standard scale called ECOG, scored 0 or 1)
  • People who have been diagnosed through a tissue biopsy with invasive breast cancer that has spread or cannot be cured or surgically removed
  • People who have at least one tumour that can be measured using standard imaging guidelines (called RECIST 1.1)
  • People who have not previously been treated with a type of medication called an antibody-drug conjugate
  • People who have received no more than one previous chemotherapy treatment for advanced breast cancer
  • People whose tumour has been tested for hormone receptor status — those with hormone receptor-positive cancer may have had up to two previous hormone-based treatments for advanced disease
  • People whose breast cancer is classified as "HER2-low" or "HER2-ultralow" based on specific laboratory test results (confirm with trial site for exact test details)
  • People whose kidneys, liver, blood, and other organs are functioning well enough to meet the trial's requirements

Who may not be able to join:

  • People who have a history of blood clots in veins or arteries
  • People who have uncontrolled ongoing health conditions such as diabetes, high blood pressure, lung disease, or liver cirrhosis
  • People who have an active infection that requires treatment with medication
  • People who are currently pregnant or breastfeeding
  • People who have cancer that has spread to the brain or the lining around the brain or spinal cord

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wenjin Yin, M.D., Renji Hospital,School of Medicine, Shanghai Jiaotong University

Phone: 86(21)68385569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
4 May 2023
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov